CBL-514 Injection for Subcutaneous Fat

This trial tests a treatment called CBL-514 to determine its effectiveness in reducing belly fat. It targets individuals who previously participated in a study with this injection or a placebo. Participants must maintain their current lifestyle and have completed a prior related study. The goal is to understand the long-term effects of CBL-514 on reducing abdominal fat. As a Phase 3 trial, this study represents the final step before FDA approval, allowing participants to contribute to the potential availability of a new treatment.

Research has shown that CBL-514 injections are generally safe and well-tolerated. In earlier studies, no serious side effects were reported, and participants experienced a reduction in belly fat that increased with higher doses. Specifically, the more they received, the better it worked. Studies also found that CBL-514 can significantly reduce fat under the skin without causing major problems. Most participants in these trials did not experience any serious issues, making it a promising option for reducing fat.¹²³⁴⁵

Unlike other treatments for reducing subcutaneous fat, CBL-514 injection works by targeting and breaking down fat cells directly, thanks to its unique active ingredient. Most standard treatments, like liposuction or non-invasive methods such as cryolipolysis, focus on physically removing or freezing fat cells, which can be more invasive or take longer to see results. Researchers are excited about CBL-514 because it offers a less invasive alternative with the potential for quicker and more targeted fat reduction. This could lead to a more comfortable and efficient option for patients looking to reduce localized fat deposits.

Research has shown that CBL-514 injections can help reduce subcutaneous belly fat. In one study, 69.6% of participants who received CBL-514 lost at least 150 mL of fat in 8 weeks, while no one in the placebo group achieved this result. Another study found that 75% of participants experienced a noticeable reduction in fat according to the Abdominal Fat Rating Scale. This treatment also reduced fat volume by about 25%, making it a promising non-surgical option for fat reduction. Overall, evidence suggests that CBL-514 effectively targets and reduces unwanted fat. Participants in this trial will receive either the CBL-514 injection or a placebo comparator to further evaluate its effectiveness.¹²³⁵⁶